This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
The patient demographics have been obtained though direct communication with the Author.
Zhao Y, et al. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. Cancer Medicine 9: 8821-8831, No. 23, Dec 2020. Available from: URL: https://doi.org/10.1002/cam4.3491